Yahoo Alias is "NUTMEG"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Boatgirl..If you can't take the heat get out of the kitchen..Seems not to long ago you blasted me for comments made on this board.. CYA!!
DC100
Thoughts on ITET from Wise Investment post.tia
DC100
OT-1-3 inches snow this morning! May 7th..lol spokane wash..I better chain up..
DC100
DNAPrint Partners with Altura to Expand Research and Product Development
SARASOTA, Fla.--(BUSINESS WIRE)--May 7, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP - news) announced today that it has teamed with Altura, LLC of Aliso Viejo, CA to expand its research and product development efforts to address a number of undisclosed prescription drugs.
Altura will provide DNAPrint with clinically phenotyped samples for an undisclosed class of drugs, and DNAPrint will use the samples for population genomics research aimed at developing chemopredictive tests for an individualization of therapy. Drugs of the class targeted by the agreement exhibit markedly variable response rates and adverse events in the patient population. Because of this, a significant number of patients are exposed to unnecessary health risks for long periods of "treatment" time until the right drug and/or dose is found through trial and error. Due to the size of the market for the class of drugs, the agreement could have substantial implications for the company's quest to grow long-term earnings potential.
The agreement will compliment DNAPrint's current collection efforts, and enhance DNAPrint's multi-drug consent databank by 500 patients over the course of 2002. Last year, DNAPrint successfully completed a similar project with Pharsight corporation (Nasdaq:PHST - news), but DNAPrint continues to collect most of its specimens using its own private network of Florida physicians. The agreement expands to 18 the list of FDA-approved drugs for which DNAPrint is now developing pharmacogenomics classifiers, or chemopredictive tests.
With this agreement, DNAPrint gains access to Altura's expertise, which include project planning, implementation, obtaining IRB approval and collecting qualified specimens and relevant clinical data from patients throughout the US who are taking selected medications. Due to their large number of clinical relationships and knowledge of organized health systems, Altura is particularly adept at collecting data and enrolling large number of patients and physicians in an efficient manner. Terms of the agreement remain undisclosed.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.
About Altura, LLC:
Altura provides a variety of development and implementation services to the healthcare, clinical research, pharmaceutical, medical device and biotech industries. The company's focus is on facilitating the effective conduction of health outcomes programs, clinical studies and business development activities. Altura's in-depth knowledge of organized systems of healthcare, study sponsors, regulatory requirements and the clinical research industry allow for a unique offering of standard or customized services. For more information about Altura please visit http://www.altura2000.com or contact Pete Fronte, President, at 949-330-6160.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
--------------------------------------------------------------------------------
Contact:
DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400
ccastillo@dnaprint.com
Frankfurt 14:01 0,200 +0,030 +17,65% 26.240
Seems Attendence was low at all these shareholder meetings.Does not seem to much interest right now..Were any of the many questions shareholders posted asked to HRCT mgmt at meeting held the last week?
DC100
gustavgans you are just getting pissed NOW!! WoW you have more patience then me.. Damn i was pissed long ago..The sick thing is i want to buy more..
DC100
Yes MBR i remember the good old days too..I also remember thinking when HRCT got on the GEM and other exchanges we would never sleep..HRCT 24/7 lol
DC100
We will get 1st Qtr 2002 results may 15th right?
Will we show more profits?
Looking to buy more soon and wonder where the btm is..
DC100
I too am very dissapointed about HRCT blowing off the spin off shares of the other companys..That promise was dangled in fron of us like a carrot when HRCT was flying high..That was the main reason i never sold to take some off the table was that promise.Same on me Mr Greedy.HRCT should have never promised something they could not deliver..I guess they call that (IPFLS)Inaccurate Positve forward looking statements.
DC100
Iman you have to like his name..lol
Iman he has a point.. he did not spin it.. he asked what some of us were thinking..
DC100
HRCT has a BIG future ahead of her..2 clints are better then ZERO!2 + 2 = 4 4 + 4 = 46
DC100
how many were there to hear about HRCT? TIA.
Iman.Hope WC has someone to talk too when he arrives at meetings.Must not be much to post for any one who went to meetings.Yes Iman anyone who says they were going to be there would at least post there comments like in the past..Heck i remember everyone staying up late and all the ones at the meetings racing back to post all the information from there notes..The good old days..Why not now?
They were not on the pay roll were they Iman..Like sinoknowlege and a few others..Yes i think they were on the pay roll..
JMHO
DC100
WC prob flying 1st class all the way.
All CEO fly 1st class.
Iman i will just keep my mouth shut!How is RB today?
DC100
Can,t believe only 1 person from IHUB or RB went to meeting last night and no report.This is starting to get very OLD!! The sad thing is i will prob buy more when HRCT drops to 0.15's
DC100
Tin..maybe news comming and they can't report till PR comes out.
just trying to be positive..
DC100
Any notes from meeting tonight? Who was there?
DC100
reverse split = kiss of death = im out of HRCT
DC100
MisterEC are they thinking about a Reverse Split soon?
(A reverse of the split is being looked into by the six on the board: Phan, Tang, Yang, Louie, and Ohri. (That is five, I know)
Any long here care to go toe to toe with OC about his post on RB? I'm waiting!!He has a few good points to ask WC at shareholders meeting don't you think..
DC100
By: OCErnie
20 Apr 2002, 04:47 PM EDT Msg. 181735 of 181747
After all that waiting for the 10K, how odd it is that o one has had much to say about it here.
There isn't a whole lot of new information in the 10K, but no HRCT SEC filing is going to lack the odd interesting tidbit or two:
HRCT now has 76.3 million common shares outstanding, as of 3/7/02. That's a 2.4 million share increase just since 12/31/01 and 10.2 million more than at 12/31/00. (Taking into account the 4.0 million "Kwok" shares that were cancelled in late 2001, HRCT has issued about 14.2 million net shares since 12/31/00.)
The Sinobull/GTCI "reverse" merger is now expected to take place by 5/31/02.
FTL "is debating to phase out of the financial paging service business in Hong Kong and is considering to physically relocating to China." (It appears little hotsearch is the English language grammar consultant on these official HRCT documents.)
HRCT has received $157,829 from Edda, the lucky firm that has promised to pay quarterly interest on the $2.86 million it owes HRCT for UAC Online. (Anyone want to bet whether HRCT will ever see cold, hard cash for the entire amount of the $2.7 million balloon payment due on 12/1/06?)
HRCT's joint venture agreement with Wind Info has been terminated.
As of 3/10/02, no Hartcourt affiliate had sold any of Equis's Metastock software in China. HRCT's "conditional territory exclusivity" will expire on 5/31/02.
Hartcourt was unable to pay to Elephant Talk's selling shareholders the $1.25 million due on 2/16/02. Negotiations to extend the payment date are ongoing.
The Innostar joint venture, created on 10/20/99, still does not have the necessary government approvals/licenses.
HRCT's right to increase its interest in Beijing Total Solution Systems has expired with no intention for further investment in TSS.
HRCT still has a substantial amount of money "lent" to companies it once intended to buy or form a joint interest with.
The China Law joint venture, which was first agreed on 4/8/00, still has not received the necessary government "publication rights."
The $35 million Swartz "equity line" is still being quoted by HRCT as a potential source of funds, although HRCT management has previously clearly said they have no intention of using it unless HRCT's share price rises dramatically.
The fiction of Kwok's elusive $11 million as a likely source of future funding finally went away and the 4,000,000 shares HRCT had issued to him nearly two years ago without receiving any payment were cancelled.
Dr. Ching's one year employment contract provides him a salary of $120,000 (that's US, not HK). He'll also receve a $180,000 incentive bonus (based on undisclosed targets) and 300,000 options to purchase HRCT shares at $0.65 apiece.
On 3/27/02, HRCT had to borrow $125,000 from an undisclosed source - money is still tight on the good ship Lolliphan.
The $2.9 million Hogue judgment is still in place (and is cited by HRCT's auditors as having a potentially "significant adverse impact on the Company...")
As of 3/10/02, HRCT claims to have 11,344 shareholders - an amazing number considering that the company had only a shade more than that number back when its share price was 50 times higher than its current price.
In 2001 HRCT wrote down another $1.8 million worth of the value of still more of its intangible software development costs and goodwill related to overpriced acquisitions. (The writedowns were as follows: FTL - $934,884; Sinobull - $742,207; StreamingAsia - $109,171) Yet another subject on which HRCT's own CPA ("chief public apologist") badly missed the mark with his talk of intangible vs. intangible assets.
HRCT recognized a $1,060,371 "gain" on the sale of UAC, only because Edda agreed to buy UAC at HRCT's original cost, which had previously been written down by the amount of, you guessed it, $1,060,371. What great good fortune for HRCT it was able to find a sucker, er, sophisticated investor, like Edda.
The 5 million common shares Phan donated to HRCT in late 2001 were given to an unidentified creditor of HRCT to repay a $1,862,630 loan. Those 5 million shares were only worth about $1 million, so it appears this generous creditor took quite a bath on its loan to HRCT. (And as MBR has pointed out, HRCT orginally claimed this gift would "enable Hartcourt to reduce its outstanding shares.")
- - - -
That's it for now. More later. ;)
- - - - -
HRCT,s future looks good!
Hartcourt Companies Inc Quarterly Income Statement Display Annual Data
More filings for Hartcourt Companies Inc available from EDGAR Online. Get a Free Trial to EDGAR Online Premium
Income Statement Balance Sheet Cash Flow Statement
Period Ending: Dec 31, 2001 Sep 30, 2001 Jun 30, 2001 Mar 31, 2001
Total Revenue $4,680,453 $3,809,526 $1,877,865 $253,361
Cost Of Revenue $3,258,160 $3,200,375 $1,294,404 $4,840
Gross Profit $1,422,293 $609,151 $583,461 $248,521
Operating Expenses
Research And Development N/A N/A N/A N/A
Selling General And Administrative Expenses $2,989,440 $1,276,095 $1,868,417 $1,245,240
Non Recurring $1,785,262 N/A N/A N/A
Other Operating Expenses $482,340 $535,986 $326,854 $133,133
Operating Income ($3,834,749) ($1,202,930) ($1,611,810) ($1,129,852)
Total Other Income And Expenses Net ($442,370) ($324,541) $389,305 ($163,261)
Earnings Before Interest And Taxes ($3,635,200) ($1,527,471) ($1,330,298) ($1,185,320)
Interest Expense $73,418 $44,094 $38,145 $40,511
Income Before Tax ($3,708,618) ($1,571,565) ($1,368,443) ($1,225,831)
Income Tax Expense N/A N/A N/A N/A
Equity Earnings Or Loss Unconsolidated Subsidiary N/A N/A N/A N/A
Minority Interest ($11,845) $264,556 $281,415 $107,793
Net Income From Continuing Operations ($4,362,382) ($1,307,009) ($979,235) ($1,225,831)
Nonrecurring Events
Discontinued Operations ($52,789) $735,208 N/A N/A
Extraordinary Items $1,506,853 $355,777 N/A N/A
Effect Of Accounting Changes N/A N/A N/A N/A
Other Items N/A N/A N/A N/A
Net Income ($2,908,318) ($216,024) ($979,235) ($1,225,831)
Preferred Stock And Other Adjustments N/A N/A N/A N/A
Net Income Applicable To Common Shares ($2,908,318) ($216,024) ($979,235) ($1,225,831)
More filings for Hartcourt Companies Inc available from EDGAR Online. Get a Free Trial to EDGAR Online Premium
EDGAR Online: Research People in this company / Full text Search
ADVERTISEMENT
--------------------------------------------------------------------------------
Plea from Alan:
Dear Friends:
We need your help urgently. As you know, our CEO and
President, Dr. Wallace Ching will visit 6 cities in
the US and Germany to meet with shareholders and
investors. The road show is the beginning of a new PR
campaign to gain maximum public exposure for Hartcourt
and its subsidiaries. Our achievements in operational
and financial results such as revenue growth, market
position, business models in a post-WTO China are
best-kept secrets in the capital markets. It’s time we
tell our story to the world.
We ask you to help us notify the local media and the
local investment community of these meetings so we
could reap the possible benefit of a printed article,
a short TV segment, an analyst report, or any
publicity that might result.
We attach herewith an invitation letter which we ask
you to send via Email or fax to the local media, the
local brokerages, the fund managers and any potential
investor you could think of. We also enclose a list of
media contacts in each city where the meeting takes
place. The media will turn out if they receive enough
personal invitation from each shareholder. Let them
come and hear the Hartcourt story straight from Dr.
Ching. We think they will be fascinated by our China
business and its potential.
Of course, make sure that you will reserve the time to
attend the meeting yourself (if the location is not
too far from your place). We count on your support to
make Dr. Ching’s meetings the most successful road
show of this company.
Thank you in advance,
All Members of the Hartcourt Team
maybe a stop in n.idaho on the way to windy city..lol
DC100
Thoughts on fonx please..good entry point?
tia DC100
Green is GOOD!!eom
HARTCOURT Frankfurt 13:15 0,210 +0,020 +10,53%
What NO visit to N.Idaho? Darn missed it again..lol
DC100
'cold hearted orb that rules the night
removes the colors from our sight
red is gray and yellow white
but we deceide which is right
and which is an illusion'
Hey moody how you doing!
DC100 some where on vacation
blazers vs knicks at the rose garden TONIGHT!!
DC100
Another thought..
April fools!! HRCT day will come in time..
DC100
HRCT + 124% pre MKT!!
HARTCOURT Frankfurt 28 Mrz 0,210 +0,010 +5,00% 27.511
I love these PR,s that come out for our german friends!
DC100
I like this part from PR!!
These agreements, and the very positive response for Sinobull's Chinese version of MetaStock, Sinobull Wireless PDA and Sinobull Data services at the recent industry leading Securex Trade Show continue to add to our momentum in the financial products and services sector. Sinobull's data feeds on commodities and foreign exchanges continue to be the best in the financial industry, our data is being used daily by multiple media sources, and our research reports are among the most respected in the nation.''
When is filing due? Or will it be HRCTE
DC100
Is this new or just a rehash of old stuff about cable t.v like CNBC ect..We already knew about t.v and real time information HRCT was going to do someday.
DC100
Iman and MBR they call it ( cost of doing business boys!) When will they care about sharholder value?
DC100